According to, "Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash, giving it access to the target’s approved drugs for skin cancer and the targeted cancer medicines in its pipeline." Last year, Arrays's oral combination treatment was approved by the Food and Drug Administration for patients with the deadliest form of skin cancer.


More videos